Figure 1From: Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay Diagram of the mevalonate pathway. N-bisophosphonates inhibit FPP-synthase, leading to accumulation of IPP, which generates ApppI from AMP. ApppI has been found to be toxic to cells [19], while statins inhibit HMG-CoA reductase.Back to article page